Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

BioDrugs

Volumn 30, Issue 4, 2016, Pages 321-338

  Liu, Jennifer ^a   Eris, Tamer ^a   Li, Cynthia ^a   Cao, Shawn ^a   Kuhns, Scott ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABP 501; ADALIMUMAB; BIOSIMILAR AGENT; DNA; GLYCAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG RECEPTOR BINDING; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HOST CELL; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PROCESSING; STORAGE; TEMPERATURE STRESS; THERMOSTABILITY; ANIMAL; CAPILLARY ELECTROPHORESIS; CHEMISTRY; CHO CELL LINE; CIRCULAR DICHROISM; CRICETULUS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECTS; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; ISOELECTRIC POINT; PEPTIDE MAPPING; PHOTON CORRELATION SPECTROSCOPY; PROCEDURES; ULTRACENTRIFUGATION;

ADALIMUMAB; ANIMALS; BIOSIMILAR PHARMACEUTICALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; CRICETULUS; DRUG STABILITY; DYNAMIC LIGHT SCATTERING; ELECTROPHORESIS, CAPILLARY; ISOELECTRIC POINT; PEPTIDE MAPPING; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; ULTRACENTRIFUGATION;

EID: 84979713298     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-016-0184-3     Document Type: Article

References (36)

1. AbbVie. Humira (adalimumab) injection [prescribing information]. North Chicago: AbbVie Inc; 2015.
2. Tebbey PW, Varga A, Naill M, Clewell J, Venema J. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs. 2015;7(5):805–11.
3. European Medicines Agency. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 7 July 2016.
4. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Technical Report Series no. 977. Annex 2. 2013. http://who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf. Accessed 7 July 2016.
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. Accessed 7 July 2016.
6. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed 7 July 2016.
7. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). http://www.ebe-biopharma.eu/newsroom/download/58/document/ema:chmp:bwp:247713:2012.pdf. Accessed 7 June 2016.
8. U.S. Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 7 July 2016.
9. European Medicines Agency. European public assessment reports. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submitudy. Accessed 25 Apr 2015.
10. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5(5):621–3.
11. US Food and Drug Administration. FDA approves first biosimilar product Zarxio [press release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed 7 July 2016.
12. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163–77.
13. Beck A, Dimer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito D, et al. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Analyt Chem. 2013;48:81–95.
14. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs. 2010;2(4):379–94.
15. Chen SL, Wu SL, Huang LJ, Huang JB, Chen SH. A global comparability approach for biosimilar monoclonal antibodies using LC-tandem MS based proteomics. J Pharm Biomed Anal. 2013;80:126–35.
16. Cao J, Sun W, Gong F, Liu W. Charge profiling and stability testing of biosimilar by capillary isoelectric focusing. Electrophoresis. 2014;35(10):1461–8.
17. Li Y, Fu T, Liu T, Guo H, Guo Q, Xu J, et al. Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells. MAbs. 2016;8(5):951-60.
18. Lopez-Morales CA, Miranda-Hernandez MP, Juarez-Bayardo LC, Ramirez-Ibanez ND, Romero-Diaz AJ, Pina-Lara N, et al. Physicochemical and biological characterization of a biosimilar trastuzumab. Biomed Res Int. 2015;2015:427235.
19. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89(15):1110–6.
20. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527–40.
21. Damen CW, Chen W, Chakraborty AB, van OM, Mazzeo JR, Gebler JC, et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom. 2009;20(11):2021–33.
22. Vanhoenacker G, Vandenheede I, David F, Sandra P, Sandra K. Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests. Anal Bioanal Chem. 2015;407(1):355–66.
23. Gahoual R, Burr A, Busnel JM, Kuhn L, Hammann P, Beck A, et al. Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. MAbs. 2013;5(3):479–90.
24. Humira (adalimumab) [prescribing information]. North Chicago: Abbott Laboratories; 2005.
25. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J. 2000;78(3):1606–19.
26. Verardo ML, Carvalho JG, Delgado DN, Kuhns ST. Accuracy and sensitivity of residual DNA detection by QPCR is not predicted by target copy number. Biotechnol Prog. 2012;28(2):428–34.
27. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124–31.
28. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949–59.
29. Li P, Jiang N, Nagarajan S, Wohlhueter R, Selvaraj P, Zhu C. Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16a) binding to IgG ligands. J Biol Chem. 2007;282(9):6210–21.
30. Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40.
31. Kaur PP, Chow V, Zhang N, Moxness M, Markus R. Pharmacokinetic equivalence of ABP 501 relative to adalimumab: results from a randomized, single-blind, single-dose, parallel group study in healthy subjects [abstract]. Arthritis Rheum. 2014;66(10 suppl):S661–2.
32. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–73.
33. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11(6):2327–36.
34. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 2006;281(8):5032–6.
35. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, et al. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs. 2012;4(4):475–87.
36. Velayudhan J, Chen Y, Rohrbach A, Pastula C, Maher G, Thomas H, Brown R, Born TL. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs. 2016. doi:10.1007/s40259-016-0185-2.